ARIZ Precision Medicine is focused on the epigenetic changes that occur in the cancerization of a cell to develop targeted therapeutics based on the genetic differences between cancer cells and healthy cells.

Developer of amino acids designed to make valuable products in a sustainable way. The company has invented a novel enzymatic method for synthesizing noncanonical amino acids (NCAA) also called unusual or unnatural amino acids and the proprietary approach enables over 100 NCAA to be synthesized with perfect enantiopurity in just a single step, enabling clients…

A biopharmaceutical company developing prescription therapies for unmet needs in the field of Food Allergy

decreasing agricultural methane emissions using one of the most scalable resources on our planet: algae

Developer of innovative therapeutics designed to treat rare and age-related diseases. The company’s therapeutics address the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress, enabling patients and medical professionals to access suitable treatment.

The Next Advancement in Gene Therapy

Manufactures laboratory glassware and glass tools for scientific and industrial uses of all sorts.

Developer of immuno-oncolody therapeutics designed to develop biologics to treat cancer. The company’s therapeutics mainly focus on engineering next generation immunotherapies to treat cancer, addressing many of the limitations associated with current therapies, enabling patients to have access to better form of cancer treatment.

Developer of gene technologies designed to improve the efficiency and enhance the safety of CRISPR-Cas-based gene editing. The company’s technologies offer Acr proteins to control the CRISPR-Cas gene editing process to create an improved CRISPR gene, enabling companies to have an editing platform for safe and effective gene therapies.

Operator of a pharmaceutical company aimed at spearheading personalized mitochondrial medicines for patients with complex diseases, such as Alzheimer’s dementia, heart failure, and cancer. The company’s approach merges mitochondria biology with pharmaceutical drug development by drugging the proteases of the mitochondrial inner membrane, thereby providing healthcare professionals with medicines for patients with complex diseases.